

Clinacin 75 mg Tablets for Dogs

Authorised

- Clindamycin hydrochloride

Product identification

Medicine name:

Clinacin 75 mg Tablets for Dogs

Active substance:

Clindamycin hydrochloride

Target species:

Dog

Route of administration:

Oral use

Product details

Active substance and strength:

Clindamycin hydrochloride
81.42 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01FF01

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Denmark

Package description:

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 100 tablets.

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 80 tablets.

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 50 tablets.

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 30 tablets.

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 20 tablets.

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 16 tablets.

White high density polyethylene bottle with child resistant tamper evident polypropylene closure containing 10 tablets.

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Well-established use application (Article 13a of Directive No 2001/82/EC)

Marketing authorisation holder:

Chanelle Pharmaceuticals Manufacturing Limited

Marketing authorisation date:

6/03/2002

Manufacturing sites for batch release:

Chanelle Pharmaceuticals Manufacturing Limited

Responsible authority:

Danish Medicines Agency

Authorisation number:

32579

Date of authorisation status change:

6/03/2002

Reference member state:

Ireland

Procedure number:

IE/V/0112/001

Concerned member states:

Denmark Finland France Germany Greece Portugal Spain Sweden

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet